Biotech entity
BlackRock is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. That works out to roughly 0.2 stories per week across an 82-day span. At 8, the average consequence score sits above the same-window beat average of 6.3.
Last mentioned: Aug 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
BlackRock is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. That works out to roughly 0.2 stories per week across an 82-day span. At 8, the average consequence score sits above the same-window beat average of 6.3. funding accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each story carries 3.5 original sources on average, compared with 3.1 for the broader beat in this window. We currently track 2 Biotech stories that mention JPMorgan Chase, published between March 23, 2026 and June 12, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 59 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering JPMorgan Chase. Shared-story counts are live from our verified record — not editorial picks.
JPM Earnings
JPMorgan Chase reports Q1 results amid regulatory and legal headwinds.
FDA Decision Date
Expected regulatory ruling on orforglipron oral weight loss drug.
Zepbound Approval
FDA expands tirzepatide approval to include chronic weight management.
Mounjaro Launch
Tirzepatide enters the market for Type 2 Diabetes treatment.
Prometheus's $12B raise envisions an artificial general engineer that can design drug compounds autonomously, potentially cutting years from pharmaceutical R&D. The startup's biotech roots via co-founder Vik Bajaj of Verily add credibility.
Source: TechCrunch · Marina Temkin (us)
Eli Lilly (LLY) is approaching a pivotal April 10 regulatory milestone for orforglipron, its experimental oral GLP-1 receptor agonist, as it seeks to expand its $11 billion weight-loss portfolio. While the broader market faces volatility from the banking sector's upcoming earnings on April 14, the biotech industry is laser-focused on the potential shift from injectable to oral metabolic therapies.
JPMorgan Chase is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
